Brasil R Resende de Lima Oliveira, Soares D Vieira, Spina L Diniz Carneiro, Lobo P Marise, da Silva E Maria Carvalho, Mansur V Aleta, Pinheiro M F Miguens Castelar, Conceição F L, Vaisman M
Service of Endocrinology, Clementino Fraga Filho University Hospital, Medical School, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brasil.
J Endocrinol Invest. 2007 Apr;30(4):306-12. doi: 10.1007/BF03346297.
The GH deficiency syndrome in adults is characterized by changes in body composition, metabolic, cardiovascular and psychological profile. Such alterations fit the metabolic syndrome. Changes of blood pressure (BP) levels related to the presence of insulin resistance (IR) may be present in the GH-deficient adult prior to or after therapy with recombinant GH (hGH). The purpose of the study was to assess the relationship between BP and IR in GH-deficient adults after 24 months of replacement with hGH. Thirteen GH-deficient adults were studied [7 men and 6 women, with an average age of 38.6+/-14.14 yr body mass index (BMI) 25.83+/-2.26 kg/m2]. The BP was assessed by means of ambulatory monitoring of BP (AMBP), prior to the treatment and 12 and 24 months after replacement with hGH. Glucose metabolism was assessed by the homeostatic model assessment (HOMA), during the same periods. The average dosage of hGH utilized was 0.67+/-0.15 mg/day. In the analysis of BP levels, we observed a decrease of the diurnal systolic BP (SB P) (p=0.043) and a reduction of the diurnal systolic (p=0.002) and diastolic pressure loads (p=0.038). During the night there were no changes in BP levels. We observed an increase in the percentage of patients with a non-physiological nocturnal fall (non dippers) after replacement with hGH (61.53%). The mean HOMA, insulin and glucose in the fasting state did not present any statistically significant changes. Although the patients within the nondipper group had higher HOMA and insulin levels throughout the study, there were no changes in any of these parameters after GH replacement. All patients with HOMA >2.5 were within the non-dipper group, whereas all dippers had HOMA <2.5. In conclusion, 24 months of therapy with hGH do not seem to have affected glucose homeostasis, and since there is no relationship with the increase of the percentage of non-physiological nocturnal fall, we will need a longer observation time to discover the effects of this finding.
成人生长激素缺乏综合征的特征是身体成分、代谢、心血管和心理状况发生变化。这些改变符合代谢综合征。在使用重组生长激素(hGH)治疗之前或之后,生长激素缺乏的成年人可能会出现与胰岛素抵抗(IR)相关的血压(BP)水平变化。本研究的目的是评估hGH替代治疗24个月后生长激素缺乏的成年人血压与IR之间的关系。对13名生长激素缺乏的成年人进行了研究[7名男性和6名女性,平均年龄38.6±14.14岁,体重指数(BMI)25.83±2.26kg/m²]。在治疗前以及hGH替代治疗12个月和24个月后,通过动态血压监测(AMBP)评估血压。在同一时期,通过稳态模型评估(HOMA)评估葡萄糖代谢。使用的hGH平均剂量为0.67±0.15mg/天。在分析血压水平时,我们观察到日间收缩压(SBP)下降(p=0.043),日间收缩压负荷(p=0.002)和舒张压负荷(p=0.038)降低。夜间血压水平没有变化。我们观察到hGH替代治疗后非生理性夜间血压下降(非杓型)患者的百分比增加(61.53%)。空腹状态下的平均HOMA、胰岛素和血糖没有出现任何统计学上的显著变化。尽管在整个研究过程中,非杓型组患者的HOMA和胰岛素水平较高,但生长激素替代治疗后这些参数均无变化。所有HOMA>2.5的患者都在非杓型组中,而所有杓型患者的HOMA<2.5。总之,hGH治疗24个月似乎并未影响葡萄糖稳态,并且由于与非生理性夜间血压下降百分比的增加没有关系,我们需要更长的观察时间来发现这一发现的影响。